23J Stock Chart & Stats
€12.20
-€1.10(-9.40%)
At close: 4:00 PM EDT
€12.20
-€1.10(-9.40%)
Day’s Range― - ―
52-Week Range€5.68 - €22.00
Previous CloseN/A
Volume0.00
Average Volume (3M)7.00
Market Cap
€97.12M
Enterprise Value€66.85
Total Cash (Recent Filing)€53.46M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Nov 18, 2026EPS Estimate
-1.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.89
Shares Outstanding8,967,693
10 Day Avg. Volume2
30 Day Avg. Volume7
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-9.53
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€36.56Price Target Upside199.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetA debt-free balance sheet reduces near-term solvency pressure and avoids interest obligations while PMN advances its pipeline. This gives management more flexibility to direct available capital toward research and clinical development rather than debt service, although it does not eliminate financing needs.
PMN310 Safety And BiomarkersThe interim PMN310 findings support a differentiated therapeutic approach in Alzheimer’s disease, combining a favorable observed safety profile with biomarker improvements. If sustained in the completed study, this could strengthen the candidate’s clinical positioning against limitations associated with existing amyloid therapies.
Improved Equity PositionThe substantial improvement in reported equity indicates meaningful balance-sheet repair and provides a stronger capital base for continuing development than the company previously had. This supports near-term financial resilience, though the benefit is tempered by volatile historical equity and ongoing operating losses.
Bears Say
No Operating RevenuePMN has not yet established a commercial revenue stream, so its business model remains dependent on advancing clinical candidates rather than generating recurring product sales. This leaves future funding and value creation highly reliant on successful development, regulatory progress, and eventual commercialization.
Persistent Cash BurnSustained negative operating and free cash flow shows that research and operations are being funded externally instead of through internally generated cash. Continued burn can consume the available capital base and may require further financing, creating dilution risk and limiting strategic flexibility over the next several quarters.
Large Worsening Net LossThe sharply negative TTM earnings profile indicates that PMN has not demonstrated operating leverage or a path to self-funded growth. Large losses increase dependence on financing while the pipeline remains in development, and they could persist until a candidate produces meaningful commercial or partnership revenue.
ProMIS Neurosciences News
23J FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was €5.68 and its highest was €22.00 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is €97.12M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is Nov 18, 2026 which is in 70 days.
How were ProMIS Neurosciences’s earnings last quarter?
ProMIS Neurosciences released its earnings results on Aug 13, 2026. The company reported -€1.095 earnings per share for the quarter, beating the consensus estimate of -€1.18 by €0.085.
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -1.09.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 8,967,693 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
ProMIS Neurosciences reported an EPS of -€1.095 in its last earnings report, beating expectations of -€1.18. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in DE:23J
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProMIS Neurosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€36.56 (199.68% Upside)
€36.56 (199.68% Upside)
Blogger Sentiment
Bullish
DE:23J Sentiment 100%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth €26.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
496.18%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
23J Earnings Call
Q2 2026
0:00 / 0:00
23J Stock 12 Month Forecast
Average Price Target
€36.56
▲(199.68% Upside)